Introducing the Proteasome System
IN THE NORMAL COURSE OF A protein's lifetime, synthesis and degradation rate determine the half-life of both short-and long-lived proteins for cellular maintenance (119) . The proteasome is a huge protease complex and the main protein degradation system within the cell: ϳ80% of all cellular proteins are processed by the proteasome into peptides of 3-22 amino acids in length (94) . Controlled protein breakdown by the proteasome involves tagging of protein substrates with ubiquitin chains mainly linked at the lysine at position 48 (K48) via a cascade of E1, E2, and E3 ubiquitin-activating, -conjugating, and -ligating enzymes, respectively. However, ubiquitin-independent degradation by the proteasome has also been described (15, 60) . Degradation products can be used to recycle amino acids or are loaded onto major histocompatibility (MHC) class I molecules to communicate the intracellular protein composition to the immune system (33, 63) : even though Ͻ0.1% of the peptides generated by the proteasome are presented at the cell surface as antigens, this system is efficient in eliciting a cytotoxic T-cell response toward infected or malignant cells (120) . Due to the broad nature of substrates, the proteasome is involved in many essential cellular functions, such as protein quality control, transcription, immune responses, cell signaling, and apoptosis (33, 95) . Moreover, degradation of damaged and misfolded proteins is also mainly taken over by the ubiquitin-proteasome system (36, 75) . This function is of central importance to counteract the cytotoxic potential of damaged proteins that arise upon oxidative modification of amino acids and subsequent exposure of hydrophobic amino acid side chains. In the lung, proteins have been shown to be modified by reactive agents, such as those present in pollutants and cigarette smoke, or which are generated at conditions of oxidative stress during immune responses (5) . The impact of proteasome dysfunction for protein quality control and proteostasis in chronic lung diseases has recently been covered by several reviews (5, 75, 76, 81) . The consequences of proteasome dysfunction for innate and adaptive immune responses in the lung, however, have not been considered so far and will be the focus of this review.
The Proteasome's Catalytic Activity
The proteasome consists of a central 20S catalytic core particle, which is activated by proteasome regulators (Fig.  1) . Several regulators are known that bind to and thus mediate opening of the 20S proteasome for substrate entry (76) . The 19S particle is the best studied regulator: it consists of at least 18 different subunits, including ubiquitin receptors and deubiquitinating enzymes, and accounts for ubiquitin-and ATP-dependent degradation of substrates (67) . Together with the 20S, it forms the 26S/30S proteasome by binding to one or both sides of the 20S core, respectively. Two 11S types of regulators are known: the interferon (IFN)-␥-inducible heteroheptameric PA28␣/␤ and the homoheptameric PA28␥, which can only be found in the nucleus. Furthermore, two monomeric regulators, PA200 as well as PI31, have been described. Proteasome regulators have been shown to determine substrate specificity and turnover rate (105) .
The 20S proteasome consists of a barrel-shaped core particle composed of four rings comprising seven subunits each (Fig. 1) . Seven related, but distinct, ␣-subunits form the two outer ␣-rings (33) . Because the NH 2 -termini of the ␣-subunits close the entry pore and inhibit substrate entry, the 20S core particle only allows entry of unfolded proteins. Three of the seven ␤-subunits that constitute each of the two inner ␤-rings are catalytically active and confer the proteolytic capacity of the 20S proteasome. These three ␤-subunits determine the species of the 20S core particle: depending on the cell-type, cytokine milieu, or activation state of the cell, different ␤-subunits are expressed and incorporated into mature 20S (Fig. 1) . The standard 20S proteasome is expressed in every cell type and integrates the ␤1-, ␤2-, and ␤5-subunits, which cleave after acidic, basic, or hydrophobic amino acids, respectively (45) . In immune cells, however, three different ␤-subunits are constitutively expressed (103) : low molecular mass protein (LMP) 2, multicatalytic endopeptidase complex-like 1 (MECL-1), and LMP7 (also called ␤1 i , ␤2 i , and ␤5 i ). In nonimmune cells, these three so-called immunosubunits can be induced by IFN-␥ or tumor necrosis factor (TNF)-␣ signaling (2, 40) . In addition, several other stimuli have been identified that upregulate immunosubunits, including retinoic acid (118) , nitric oxide (64) , cytokines such as IL-4 (23), Toll-like receptor agonists, type I interferons (101) , and recently mammalian target of rapamycin (mTOR) signaling (121) . Given the multitude and variety of stimuli that trigger immunoproteasome subunit expression, it is tempting to rename "immunoproteasome" to "inducible proteasome," as these specialized types of proteasomes appear not to be restricted to immune responses anymore. When immunosubunits are expressed, they are preferentially incorporated into newly assembled 20S immunoproteasomes (50, 58) . Furthermore, they exhibit altered cleavage preferences compared with standard proteasomes, with a strongly reduced postacidic cleavage activity based on the ␤1/LMP2 exchange, leading to generation of peptides that are preferentially loaded onto MHC I molecules compared with peptides derived from standard proteasomes (38) . In addition, mixed proteasomes consisting of both standard and immunoproteasome subunits have been described which contribute to an even more diverse peptide pool (24) . 
Immunoproteasomes Facilitate CD8 ϩ T-Cell Mediated Resolution of Intracellular Infections
Immunoproteasomes are of crucial importance for CD8 ϩ T-cell-mediated immune responses against intracellular infections (73) . Specifically, they play an essential role at three crucial checkpoints. First, immunoproteasomes are important for negative selection of autoreactive CD8 ϩ T cells in the thymus upon development of the immune system: immunoproteasomes are expressed in medullary thymic epithelial cells, where they contribute to the generation of the cellular "self"-peptide repertoire that is presented to developing CD8 ϩ T cells (87) . Thereby, selection of only those T cells that do not bind to self-peptide/MHC I complexes is achieved (3, 39) . The remaining naive CD8 ϩ T cells migrate to lymph nodes and persist until they are activated by antigen-presenting cells (APCs) to execute their effector function and combat infections.
Second, APCs, especially dendritic cells (DC), mainly express immunoproteasomes (103). DCs are able to engulf necrotic particles of infected cells and migrate to draining lymph nodes on maturation. There they present immunoproteasomederived pathogen peptides on MHC I, together with costimulatory molecules to evoke specific CD8 ϩ T-cell responses (so-called cross-presentation). With the help of APCs, intracellular viral or bacterial infections are thus communicated to naive CD8 ϩ T cells in the lymph nodes to induce a pathogenspecific adaptive immune response. After activation, the CD8 ϩ T cells move to the site of infection and patrol the infected organ in search for their specific antigen bound to MHC I to kill the infected cell (96) .
Third, to limit pathogen replication by selective killing of infected cells, cells need to signal their infection status to patrolling activated CD8 ϩ T cells. To be recognized by CD8 ϩ T cells, infected cells upregulate immunoproteasome expression to present exactly the same immunoproteasomegenerated pathogen antigen as during CD8 ϩ T-cell activation by the APC (55, 101) (Fig. 2) . Importantly, immunoproteasomes are downregulated after the infection is resolved to limit possible autoreactivity of CD8 ϩ T cells to noninfected cells (38, 39) .
Immunoproteasomes thus enhance antigen presentation by increasing the quantity (32, 78) and/or quality of peptides for MHC I antigen presentation (38, 106) . Indeed, immunoproteasomes have been reported to shape the MHC I peptide repertoire, which was illustrated by the use of proteasome inhibitors and immunoproteasome knockout mice, either of single or of all three immunosubunits (8, 57, 113) . Accordingly, immunoproteasomes dictate expansion of CD8 ϩ Tcell clones after infection, as shown in several mouse models of viral or bacterial infections. In these models, and strongly depending on the immunodominant epitopes of the pathogen, effects of immunoproteasome (subunit) deficiency ranged from no detectable differences in virulence (18, 84) , altered antigenic peptide presentation and CD8 ϩ T cell response (6, 37, 46, 48, 89, 97, 98, 102, 110, 123) , to even increased morbidity and mortality (85, 109) . These studies emphasize the importance of immunoproteasomes during infection to enhance MHC I antigen presentation and to increase generation of pathogen-derived peptides. One well-studied example represents the influenza A virus, which is an important trigger of exacerbations in chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD) (100): two immunodominant MHC I epitopes have been shown to be differentially processed by standard and immunoproteasomes in C57BL/6 mice (123). Whether these results can be translated to influenza A human MHC I epitopes, however, has not been investigated so far.
Immunoproteasomes Protect From Autoimmunity
Intriguingly, the cell type-and tissue-specific distribution of immunoproteasomes is important for protecting the organism ϩ T cells, which might also have been primed against "self"-antigens, are thus prevented to become activated, as the IP-dependent MHC I peptide repertoire is switched back to the standard repertoire. Therefore, IPs help to protect from autoimmunity. from autoimmunity after infection. Immune cells, such as APCs, constitutively express immunoproteasomes, whereas parenchymal cells only express them in response to inflammatory cytokines, such as IFN-␥ or TNF-␣ (Fig. 2) . During CD8 ϩ T-cell priming in the lymphatic tissues, both immunoproteasome-derived pathogen antigens, but also "self"-antigens, are presented on MHC I by the APC. If a "self"-reactive CD8
ϩ T cell, despite thymic selection, would be activated during infection by an APC, the same immunoproteasome-dependent selfantigen might be presented by an infected parenchymal cell. The epitope would cease to be presented by parenchymal cells after the infection is resolved, because immunoproteasomes are gradually replaced by standard proteasomes (42) . Certain immunoproteasome-derived self-antigens are thus presented to the immune system only during infection, thereby protecting from autoreactive immune responses after resolution of infection (30, 38, 101) .
Indeed, it has been shown that immunoproteasomes are inappropriately expressed in human autoimmune disorders (29, 35, 65, 77) and experimental models of autoimmunity (7, 14) . Accordingly, the use of novel immunoproteasome-specific inhibitors has been proposed for treatment of autoimmune disorders (13, 16, 61, 63, 111) . These inhibitors have been proven to successfully counteract autoimmune responses in several experimental models of autoimmune diseases (7, 11, 47, 79, 82, 122) . Inhibition of immunoproteasomes in autoimmunity could have two beneficial and synergistic effects: 1) presentation of immunoproteasome-dependent self-antigens by parenchymal cells might be hindered; and 2) inflammatory cytokine secretion by immune cells might be dampened (79) .
Furthermore, single nucleotide polymorphisms (SNP) of proteasome subunits have been associated with autoimmune diseases, however, with partially conflicting results (an overview can be found in Supplementary Table S1 in Ref. 76 ).
Immunoproteasomes Shape Immune Cell Function and Innate Immune Responses
Beyond shaping adaptive immune reactions, proteasomes, and in particular immunoproteasomes, regulate the function of immune cells by degradation of inflammatory and immune mediators. Special interest and conflicting data exist on the role of immunoproteasomes in NF-B signaling, which might reflect cell type-specific effects or the outcome of different experimental settings (44, 49, 72) . Our own and partially unpublished data indicate that NF-B signaling is not affected by deletion of the immunoproteasome subunits LMP2 or LMP7: NF-B promotor-driven reporter gene as well as NF-B target gene expression were unchanged in alveolar macrophages of LMP2-deficient mice after LPS and IFN-␥-induced macrophage polarization (23) . Several mutations in the human PSMB8 and PSMB9 genes encoding the LMP7 and LMP2 immunoproteasome subunits, respectively, have been discovered in autoinflammatory disorders (1, 4, 17, 62, 70, 74) . In addition, mutations in other 20S proteasome subunits have been identified, leading to, e.g., reduced expression, misfolding, or impaired 20S incorporation of mutated subunits, and, therefore, changes in cellular proteostasis (17) . These diseases have been combined in the so-called proteasome-associated autoinflammatory disorders.
Cells of the adaptive immune system have been shown to be regulated by the immunoproteasome subunit LMP7: the differentiation potential of naive CD4 ϩ T helper (Th) cells to Th1/Th17 was impaired, while regulatory T-cell differentiation was enhanced in the absence or catalytic inhibition of LMP7 due to altered cellular signaling (51) . The immunological phenotype of immunoproteasome knockout mice also points toward altered proteostasis, leading to changes in immune cell function: LMP2-deficient mice display less B cells as well as reduced numbers of peripheral CD4 ϩ and CD8 ϩ T cells (44) . MECL-1 knockout mice show an altered T-cell repertoire (10), and combined deletion of both MECL-1 and LMP7 leads to hyperproliferation of T cells (22) . Inhibitors of LMP7 have also been shown to influence inflammatory cytokine production, which might add to their beneficial effects in preclinical models of autoimmunity (79) .
Less attention has been paid to the role of immunoproteasomes in innate immunity. Van Helden and colleagues (43) did not observe changes in natural killer cell education in MECL-1/LMP7 double knockout mice, but immunoproteasome deficiency in splenocytes led to their rejection only in virus-infected, but not naive recipient, wild-type mice in a natural killer cell-dependent manner. Our laboratory's own study (54) demonstrated altered polarization capacities of alveolar macrophages upon immunoproteasome subunit deficiency. These cells express high levels of immunoproteasomes. While the proinflammatory IFN-␥/LPS-induced M1 phenotype was not changed in LMP7-deficient primary macrophages, IL-4 treatment of wild-type or LMP7-deficient cells resulted in augmented M2 polarization marker gene expression, increased M2 signaling (via STAT6 and AKT), and an increase in IL-4 receptor-␣ expression already at baseline (23) . Catalytic inhibition of LMP7 with the immunoproteasome-specific inhibitor ONX-0914 led to similar results. These data were partially confirmed in a recent study by Kimura and colleagues (56): compared with wild-type animals, LMP7-deficient mice exhibited increased levels of M2 marker gene expression in white adipose tissue after high-fat diet, while there was no change in M1 marker gene expression.
Paeschke and colleagues (88) observed reduced levels of the soluble cardioprotective pattern recognition receptor pentraxin 3 upon LMP7 inhibition or genetic deletion, which was associated with exacerbated coxsackievirus B3 inflammatory injury of heart tissue. A recent study investigated the role of ONX-0914 in fungal infection and observed increased susceptibility to systemic candidiasis associated with a possible defect in neutrophil function (80) .
Until now, it is unresolved how these changes in immune cell function are mediated. Immunoproteasome deficiency has been shown to influence the transcriptome of immune cells, which might be the result of altered substrate turnover in immunoproteasome-deficient cells (57, 112, 113) . One explanation might be that immunoproteasomes increase the general pool of proteasomal catalytic capacity (50) . Immunoproteasomes may also have altered substrate specificities due to differential association with proteasome regulators, as described for PA28␣/␤ (31). The recently discovered defined interplay of immunoproteasomes with fundamental cell signaling pathways such as mTOR may also specifically regulate immune cell responses (121, 124) .
Impact of Proteasome Dysfunction on Immune Responses in Respiratory Diseases
As the lung is directly exposed to the environment, environmental stressors, such as pollutants, pathogens, and oxidants, are continuously challenging proteostasis in lung cells. By now it is well established that proteasome function is impaired by environmental insults: it has been demonstrated that pesticides, diesel exhaust, and cigarette smoke decrease proteasome activity (59, 92, 93, 116) , but also drugs such as ethanol have been shown to impair proteasome function (21, 28, 86) . Environmental challenges may affect proteasome function on different levels as summarized recently (76) . First, transcriptional regulation of proteasomes has been shown to be part of a protective response to oxidative stress (66) . In particular, induction of immunoproteasomes has been suggested to contribute to the degradation of oxidatively modified proteins in vitro and in vivo (27, 68, 90) . Seifert et al. (99) demonstrated that immunoproteasome-deficient cells needed more time to resolve IFN-␥-induced oxidatively modified, i.e., carbonylated, proteins. However, these results remain controversial (83) . Data from our group refute a protective role of immunoproteasomes in response to cigarette smoke as alveolar macrophages from COPD patients, as well as from smoke-exposed mice, exhibited reduced immunoproteasome levels similar to lung parenchymal cell lines that had been treated with cigarette smoke extract (52, 53) .
Second, dynamic changes in the composition of proteasomal complexes in the cell might serve as a quick means of the cell to cope with environmental stimuli (76). The 26S proteasome was shown to fall apart in response to oxidative stress (71, 108, 115) , whereas PA28␣/␤ assembled with 20S proteasomes originating from disassembled 26S proteasomes to protect from oxidative stress (34, 69, 91) .
Third, proteasome activity might be directly impaired by oxidative insults. We and others have recently shown that cigarette smoke impairs both standard and immunoproteasome activity in vitro and in vivo, which correlated with elevated levels of oxidative stress (52, 93, 104) . In particular, both standard and immunoproteasome activity was clearly impaired in whole lung homogenates of COPD patients in the absence of transcriptional regulation (52) .
In light of the aforementioned role of immunoproteasomes in innate and adaptive immune responses, environmental impairment of immunoproteasome function, but also genetic variations in immunoproteasome subunits, might represent a currently underestimated risk factor for the development of lung diseases (Fig. 3) .
Reduced immunoproteasome activity in response to, e.g., cigarette smoke might be harmful during pulmonary infection and in acute exacerbations: intracellular human pathogens are efficiently cleared via MHC I-dependent CD8
ϩ T-cell responses that kill the infected cell and prevent further amplification of the pathogen and thus tissue damage. The important contribution of immunoproteasomes in mounting an effective adaptive anti-viral immune response has been shown, e.g., for influenza A virus (57, 89, 123) . It is well feasible that immunoproteasome dysfunction in patients with COPD might result in impaired antiviral immune responses toward influenza A virus infection, thereby contributing to disease exacerbations, as previously proposed by our laboratory (52) .
In a murine model of asthma, LMP7-deficient mice showed reduced uptake of ovalbumin and attenuated ovalbumin-induced asthma, while responses to house dust mite were comparable (114) .
A missense SNP in the PSMB8 gene encoding the immunosubunit LMP7 was associated with an increased risk for the ϩ T cells with the same efficiency, or they might prime an altered set of CD8 ϩ T cells. These might also include autoreactive T cells specific for "self"-antigens produced by standard proteasomes that are also presented by parenchymal cells when infection is eventually resolved, thereby promoting autoimmunity. Reduced immunoproteasome activity in parenchymal cells, such as alveolar epithelial cell type (AT) I and II, might lead to delayed resolution of infection, as the infection status cannot be efficiently communicated to the immune system in the form of CD8 ϩ T cells. Prolonged infection thus could lead to more severe tissue damage and contribute to emphysema formation. Alveolar macrophages with immunoproteasome dysfunction have increased profibrotic M2 polarization capacity and might predispose to tissue remodeling, as observed in asthma and pulmonary fibrosis. development of pigeon breeder's hypersensitivity pneumonitis, a form of extrinsic allergic alveolitis (20) . However, whether missense SNPs in proteasomal genes result in alterations of protein levels, impaired 20S proteasome assembly, or altered association of 20S to its regulators, has not been analyzed so far.
Immunoproteasome dysfunction in innate immune cells might also increase susceptibility to diseases associated with type 2 immune responses: increased M2 polarization of alveolar macrophages might facilitate development of pulmonary fibrosis (23) . Indeed, alveolar macrophages of idiopathic pulmonary fibrosis patients exhibited reduced levels of immunoproteasomes (52) .
In non-small cell lung cancer, immunoproteasome expression was recently found to be a prognostic factor in cancer patients. Low levels of immunoproteasome expression were associated with reduced survival and increased recurrence of metastases (107) . It is well known that malignant cells actively suppress immunoproteasome function to evade CD8 ϩ T-cell surveillance, similar to the strategy that is used by several viruses (73) . One tactic of cancer cells is expression of a nonfunctional transcript variant of the LMP7 protein, which is not incorporated into mature 20S proteasomes. These cells are thus immunoproteasome deficient (41) . This immunoproteasome repression has been exploited for therapeutic strategies with autologous DCs of tumor patients that were pulsed with tumor antigens and small interfering RNA directed against immunoproteasomes to match the peptidome of the antigenpresenting cell with the tumor MHC I peptidome (25, 26) .
Therapeutic Interventions Targeting the Immunoproteasome in the Lung
The cell type-specific expression of immunoproteasomes in immune cells can be utilized to specifically target these cells with immunoproteasome-specific inhibitors. Compared with the Food and Drug Administration-approved proteasome inhibitors, such as bortezomib and carfilzomib, which do not discriminate between standard and immunoproteasome, these newly developed inhibitors are specific for immunoproteasome subunits (61). As mentioned above, they have successfully been used in several preclinical models of autoimmune diseases to counteract autoimmune responses in first proof-ofconcept studies. The anti-inflammatory effect of immunoproteasome-specific inhibition might also prove useful in overshooting (auto)inflammatory pulmonary diseases, such as acute respiratory distress syndrome or sarcoidosis. Chronic treatment, however, should be avoided due to the suspected side effects of increased susceptibility to virus infections (9) and the potential risk of M2 macrophage-driven fibrotic remodeling (23) . For the treatment of lung cancer, immunoproteasomespecific inhibition could represent an attractive target for combination therapy; however, the levels of active immunoproteasomes should be determined first to maximize the benefit for the patient and to limit side-effects (12, 117) .
Conclusion
With the recent success of site-specific inhibitors of the immunoproteasome in preclinical models of autoimmune diseases, exciting new possibilities have arisen that will allow therapeutic targeting of inappropriate immunoproteasome activity in disease. Moreover, these inhibitors will foster a deeper understanding of the biological role of immunoproteasomes, such as the identification of immunoproteasome-specific substrates in immune cells to unravel potential adverse effects of immunoproteasome-specific inhibitors. Furthermore, the possibility to monitor subunit-specific inhibition of the proteasome with activity-based probes (19) raises the prospect of monitoring immunoproteasome activity as a biomarker for susceptibility to infections or cancer prognosis.
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